This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Nimenrix® (meningococcal groups A, C, W-135 and Y conjugate vaccine) Prescribing Information.  Adverse event reporting information can be found at the bottom of the page.

Nimenrix Dosing and Administration

Nimenrix (meningococcal groups A, C, W-135 and Y conjugate vaccine) is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.1

Nimenrix dosing schedule:*,†,1

Recipient Age

Primary Immunisation Schedule

Infants from 6 weeks to less than 6 months of age

Two doses:
1st dose (0.5ml) given from 6 weeks of age
2nd dose (0.5ml) given 2 months after 1st dose

Infants from 6 months of age, children, adolescents and adults

Single (0.5ml) dose

Booster Dose:1

After completion of the primary immunisation course in infants 6 weeks to less than 12 months of age, a booster dose should be given at 12 months of age with an interval of at least 2 months after the last Nimenrix vaccination.

In previously vaccinated individuals 12 months of age and older, Nimenrix may be given as a booster dose if they have received primary vaccination with a conjugated or plain polysaccharide meningococcal vaccine.

Method of administration:1

  • Immunisation should be carried out by intramuscular injection only
  • The recommended injection site is the anterolateral aspect of the thigh in infants. The anterolateral aspect of the thigh or deltoid muscle is the recommended injection site for individuals from 1 year of age

*See prescribing information for further information

†Nimenrix should be used in accordance with official recommendations

Nimenrix Reconstitution and Administration

Nimenrix is available as a single pack with two needles for reconstitution and administration (23G blue and 25G orange, 25mm).2 Nimenrix is supplied as powder in a vial and solvent in a pre-filled syringe. The vaccine is reconstituted with the solvent presented in the pre-filled syringe.  These components require reconstitution prior to administration.1

How is Nimenrix reconstituted?1​​​​​​​


In one hand, hold the syringe barrel (avoid holding the syringe plunger) and unscrew the syringe cap by twisting it anti-clockwise.


Attach the needle to the syringe by twisting it clockwise into the syringe until it locks, then remove the needle protector.


Inject the solvent from the syringe into the vial containing powder to reconstitute the vaccine components.


After all the solvent has been injected into the vial, shake well to ensure all the powder has dissolved.

How is Nimenrix administered?1


Once reconstituted, inspect the solution. Nimenrix should appear as a clear, colourless solution. If any foreign particulate matter is visible or there is a variation in the physical appearance, the vaccine should be discarded.


Using a new needle, administer 0.5 ml of reconstituted Nimenrix as a single intramuscular injection.


Dispose of any unused product or waste material in accordance with local requirements.

Visuals sourced and adapted from​​​​​​​

View and download a Nimenrix reconstitution and administration guide.

Download now

How should Nimenrix be stored?1

Before reconstitution – Nimenrix should be stored in the refrigerator between 2°C and 8°C in its original packaging. It has a shelf life of 4 years, but the expiry date on the packaging should always be checked prior to use.

After reconstitution – Nimenrix should be used promptly following reconstitution. Although delay is not recommended, stability has been demonstrated for 8 hours at 30°C after reconstitution. If the vaccine is not used within 8 hours, it should not be administered.

  1. Nimenrix. Summary of Product Characteristics, United Kingdom, Pfizer Ltd. Available here
  2. Pfizer data on file, February 2020.
PP-NIM-GBR-0247. March 2021

Ask Pfizer

Contact our Pfizer Vaccines UK team 

Contact Us

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020